Cargando…

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

BACKGROUND: Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β(3)-adrenergic receptor agonist for the treatment of OAB—significantly improved daily number of urge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staskin, David, Frankel, Jeffrey, Varano, Susann, Kennelly, Michael, Newman, Diane K., Rosenberg, Matt T., Shortino, Denise D., Jankowich, Rachael A., Mudd Jr, Paul N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159226/ https://www.ncbi.nlm.nih.gov/pubmed/35685566 http://dx.doi.org/10.1155/2022/6475014

Ejemplares similares

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
por: Weber, Michael A., et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Comment on: update on the management of overactive bladder
por: Staskin, David
Publicado: (2022)

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial
por: Lacy, Brian E., et al.
Publicado: (2022)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
por: Hsiao, Sheng-Mou, et al.
Publicado: (2019)

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

Development of oxybutynin chloride topical gel for overactive bladder
por: Lucente, Vincent R, et al.
Publicado: (2011)

Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions
por: Staskin, D R, et al.
Publicado: (2008)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Sacral neuromodulation in overactive bladder: a review and current perspectives
por: Sukhu, Troy, et al.
Publicado: (2016)

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

Efficacy of interferential low frequency therapy for elderly wet overactive bladder patients
por: Oh-oka, Hitoshi
Publicado: (2008)

THE DEFORMABILITY AND THE WETTING PROPERTIES OF LEUCOCYTES AND ERYTHROCYTES
por: Mudd, Stuart, et al.
Publicado: (1931)

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density
por: Yamamoto, Shota, et al.
Publicado: (2023)

Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care
por: Staskin, David R., et al.
Publicado: (2012)

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Drying and wetting of building materials and components
por: Delgado, JMPQ
Publicado: (2014)

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2014)

Dry computational approaches for wet medical problems
por: Emmert-Streib, Frank, et al.
Publicado: (2014)

Gecko Adhesion on Wet and Dry Patterned Substrates
por: Stark, Alyssa Y., et al.
Publicado: (2015)

Strong Wet and Dry Adhesion by Cupped Microstructures
por: Wang, Yue, et al.
Publicado: (2019)

Comparison of Tympanoplasty Results in Dry and Wet Ears
por: Naderpour, Masoud, et al.
Publicado: (2016)

Spreading of soap bubbles on dry and wet surfaces
por: Pfeiffer, Patricia, et al.
Publicado: (2020)

Reversible and Irreversible Processes in Drying and Wetting of Soil
por: Bodale, Ilie, et al.
Publicado: (2019)

Wetting transitions in droplet drying on soft materials
por: Gerber, Julia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6nn436lj7tdo9s5596s82n62ko